RxDoctor Payments Data

Michael Fradley, MD

Cardiovascular Disease · Tampa, FLNPI 1427194166

Payments from drug & device makers

$176,264in general payments, 2019–2025

Across 106 payments — averaging $1662.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$72K
  • Medtronic$39K
  • Pfizer$22K
  • Abbott$13K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$12K
  • Takeda Pharmaceuticals U.S.A., Inc.$5K
  • plus $14K from 11 others
$7,960in research payments, 2019–2025

Across 4 payments — averaging $1990.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$8K

What the payments were for

  • Consulting fees$39,09648%
  • Speaking & faculty fees$36,84346%
  • Travel & lodging$2,3393%
  • Food & beverage$2,6373%
  • Education$210%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$176,264 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$122,087
Medicare patients
2,450
Services billed
4,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$106,078
EntrestoSacubitril/Valsartan45$68,066
JardianceEmpagliflozin23$36,295
Valsartan84$3,538
Rosuvastatin Calcium169$3,276
Metoprolol Succinate141$2,102
Atorvastatin Calcium64$906
Torsemide26$725
Carvedilol66$715
Ezetimibe17$715
Losartan Potassium60$638
Furosemide48$616
Amlodipine Besylate53$419
Spironolactone26$244
Metoprolol Tartrate17$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21,757$106,07884 claims
NovartisEntresto$125$68,06645 claims
Boehringer IngelheimJardiance$21$36,29523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →